Lose weight and keep it off with
diet, exercise and Qsymia1,2
Clinically proven results in 56-week Qsymia studies1,2
See the average results of patients who were participating in the studies at the 12, 28 and 56-week time points. These are important time points to help your healthcare provider evaluate your status and assess your treatment plan.1,2‡
‡The results presented here are from the combined studies supporting FDA approval of Qsymia. The dosing schedule in those studies differ from the dosing schedule that your physician may recommend. As a result of this dosing differential, your results may vary depending on your weight, BMI, diet, activity level, dose of Qsymia, and other factors.
Qsymia was studied in 2 large trials that involved 3754 patients whose BMI was 27 kg/m2 or greater. For the subjects in the 2 studies the average baseline weight was 256 lbs and 227 lbs, and the average baseline waist circumference was 47 inches and 45 inches. Patients were randomized to placebo, phentermine 3.75 mg/topiramate 23 mg (starter dose), phentermine 7.5 mg/topiramate 46 mg (recommended dose), or phentermine 15 mg/topiramate 92 mg (top dose). In these trials, it was recommended that patients eat a well-balanced diet and reduce their caloric intake by 500 kcal/day.
The chart presents data for patients who completed treatment at each time point. Some patients left the study or stopped taking Qsymia prior to completing the full 56 weeks. The drop off rate for placebo was 47% (687/1477), recommended dose was 31% (150/488) and top dose was 38% (561/1479). The most common reasons (>2% of patients) were: adverse events, patients lost to follow up, patients who withdrew consent, or lack of efficacy.
Analysis of all patients (including those who dropped off) results in slightly smaller reductions in weight and waist circumference. Weight loss in all patients was 4.7 lbs, 14.1 lbs, and 17.2 lbs with placebo, recommended dose, and top dose, respectively, at 12 weeks; 5.4 lbs, 19.5 lbs, and 24.3 lbs with placebo, recommended dose, and top dose, respectively, at 28 weeks; and 3.8 lbs, 19.5 lbs, and 24.7 lbs with placebo, recommended dose, and top dose, respectively, at 56 weeks. The reduction in waist circumference was 1.1 inches, 2.2 inches, and 2.5 inches with placebo, recommended dose, and top dose, respectively, at 12 weeks; 1.3 inches, 3.2 inches, and 3.7 inches with placebo, recommended dose, and top dose, respectively, at 28 weeks; and 1.2 inches, 3.4 inches, and 4.0 inches with placebo, recommended dose, and top dose, respectively, at 56 weeks.1,2
You don’t have to try to lose weight on your own.
Extensively studied and prescribed, Qsymia is the once-daily pill that helps you manage your weight-loss plan and set realistic expectations.1,2
Clinically proven results
Qsymia’s results have been clinically tested in two long-term studies with over 3,700 participants.1
Used by half a million patients
Over 500,000 patients have used Qsymia to help achieve their weight‑loss goals.2
2 million Qsymia prescriptions filled
Over 2 million Qsymia prescriptions have been filled by patients. Source: McKesson Specialty Health, 2017.
The NEW Qsymia Advantage Program makes it easier for you to get Qsymia, manage your plan and achieve your weight-loss goals.
THE PROGRAM INCLUDES THE NEW
Home Delivery Pharmacy
- Exclusive $98 flat pricing on Qsymia for cash patients§ — no savings card required
- Order direct online and have Qsymia delivered to your door — hassle free!
Take control of your hunger and cravings
It can be frustrating coping with the daily cycle of hunger and cravings. Willpower alone is not enough. Qsymia can give you around the clock control.1Learn how Qsymia works